Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Nilutamide, sold under the brand names Nilandron and Anandron, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer. It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women. It is taken by mouth.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Nilutamide. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
prostate cancer flutamide testosterone bicalutamide effects levels treatment liver monotherapy hormone therapy available used transgender side antiandrogen drug feminization enzymes
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Nilutamide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Nilutamide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Nilutamide | ATC code | L02BB02 (WHO) | 1.00 | infobox |
| Nilutamide | Bioavailability | Good | 1.00 | infobox |
| Nilutamide | CAS Number | 63612-50-0 Y | 1.00 | infobox |
| Nilutamide | ChEBI | CHEBI:7573 Y | 1.00 | infobox |
| Nilutamide | ChEMBL | ChEMBL1274 Y | 1.00 | infobox |
| Nilutamide | ChemSpider | 4337 Y | 1.00 | infobox |
| Nilutamide | CompTox Dashboard (EPA) | DTXSID3034165 | 1.00 | infobox |
| Nilutamide | Drug class | Nonsteroidal antiandrogen | 1.00 | infobox |
| Nilutamide | DrugBank | DB00665 Y | 1.00 | infobox |
| Nilutamide | ECHA InfoCard | 100.153.268 | 1.00 | infobox |
| Nilutamide | Elimination half-life | Mean: 56 hours (~2 days) Range: 23–87 hours | 1.00 | infobox |
| Nilutamide | Excretion | Urine: 62% Feces: <10% | 1.00 | infobox |
| Nilutamide | Formula | C12H10F3N3O4 | 1.00 | infobox |
| Nilutamide | IUPHAR/BPS | 2864 | 1.00 | infobox |
| Nilutamide | KEGG | D00965 Y | 1.00 | infobox |
| Nilutamide | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Nilutamide | MedlinePlus | a697044 | 1.00 | infobox |
| Nilutamide | Melting point | 149 °C (300 °F) | 1.00 | infobox |
| Nilutamide | Metabolism | Liver (CYP2C19, FMOTooltip flavin-containing monooxygenase) | 1.00 | infobox |
| Nilutamide | Metabolites | At least 5, some active | 1.00 | infobox |
| Nilutamide | Molar mass | 317.224 g·mol−1 | 1.00 | infobox |
| Nilutamide | Other names | RU-23908 | 1.00 | infobox |
| Nilutamide | Pronunciation | nye-LOO-tah-mide | 1.00 | infobox |
| Nilutamide | Protein binding | 80–84% | 1.00 | infobox |
| Nilutamide | PubChem CID | 4493 | 1.00 | infobox |
| Nilutamide | Routes of administration | By mouth | 1.00 | infobox |
| Nilutamide | Trade names | Nilandron, Anandron | 1.00 | infobox |
| Nilutamide | UNII | 51G6I8B902 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.